Debate Continues Over Early Cognition Screening

Some argue that obtaining a timely baseline could offset subsequent delays in diagnosing Alzheimer’s.

BY ALICIA AULT
Associate Editor, Practice Trends

WASHINGTON — Some Alzheimer’s disease support groups—but not all—are stepping up calls for earlier and more frequent cognition screening, citing an aging population increasingly at risk for dementia.

The disease affects 1 in 10 people older than age 65 years, and almost half of those older than age 85 years, according to the Alzheimer’s Foundation of America. It is the seventh leading cause of death in the United States.

A cognition screen can establish a baseline, and be used to prompt referrals to clinicians who might discern the cause of memory loss or loss of executive functioning, Eric J. Hall, CEO of the New York-based APA, said in an interview. Some of these causes may be treatable, Mr. Hall said.

An Alzheimer’s diagnosis is important; knowing it early in the disease progression helps patients and families prepare, and early intervention can improve quality of life, he said.

The APA has been seeking coverage of cognition screening as part of the “Welcome to Medicare” exam. The exam is offered during the first 6 months of Medicare Part B coverage; beneficiaries pay 20% of the cost, if they have met the deductible. If they have not met the deductible, they may be liable for the exam’s entire cost. The exam covers a medical and social history; a review of risk factors for depression; a review of functional ability and level of safety; an assessment of height, weight, blood pressure, medication, and visual acuity; an ECG and interpretation of the diagnostic test; and education, counseling, and referral.

To add cognition screening would require an act of Congress, according to a spokesperson at the Centers for Medicare and Medicaid Services.

The AFA’s call for early screening and coverage was echoed by a group of experts convened by Pfizer Inc. and Eisai Inc., who issued a consensus statement in November. Pfizer and Eisai manufacture Aricept (donepezil), an Alzheimer’s drug.

In the consensus document, the Alzheimer’s Disease Screening Discussion Group urged all adults aged 65 years and older to seek cognition screening during a physical exam. Screening should be conducted on those with a strong family history of the disease or those who are concerned about memory problems, as well as on anyone admitted to an assisted-living or long-term care facility, said the seven-member panel.

Two of the panelists are paid speakers for Pfizer—Paul Solomon, Ph.D., clinical director of the memory clinic at Williams College, Williamstown, Mass., and Dr. Barry W. Rovner, director of clinical Alzheimer’s disease research at Jefferson Medical College, Philadelphia.

At a briefing on the consensus document, Dr. Solomon said there are a number of validated cognition screening tools that can be used by practitioners, including the Mini-Mental State Examination, verbal fluency test, and clock-drawing test.

“A delay in diagnosis can undermine Alzheimer’s patients and their families in terms of emotional, socially, emotionally, and medically for the future,” he said.

Dr. Rovner called for more training during medical school and residency on the importance of cognition screening, and for more education programs to target primary care physicians and the public.

Patients don’t talk to doctors about memory loss. In one study, fewer than 10% of subjects with memory-related concerns had raised the matter with their doctor.

“We have new evidence that Alzheimer’s disease is a work-related disease,” Dr. Thies said, adding that the Alzheimer’s Association encourages physicians to conduct more “cognitive surveillance.”

Once a dialog has started, physicians can determine whether the patient is just worried or if diagnostics are necessary, Dr. Thies said.

There had once been a similar debate over the utility of screening for cholesterol, he said. Now there is a consensus on how and when to measure lipids, the definition of normal cholesterol levels, and the benefits and risks of treatment.

“I have no doubt that we will get there with Alzheimer’s disease at some point; we’re simply not there yet,” Dr. Thies said.

Antioxidant Doesn’t Benefit Cognitive Performance Short Term

BY MARY ANN MOON
Contributing Writer

The antioxidant β-carotene does not improve cognitive performance among healthy older men in the short term, according to a subgroup analysis of data from a longitudinal study.

These findings add to the growing list of study results concluding that counteracting long-term oxidative stress with antioxidants doesn’t appear to protect against cognitive decline. However, it is still possible that long-term treatment with β-carotene may confer “modest” neuroprotection, reported Francine Grodstein, Sc.D., and her associates in the Physicians’ Health Study (PHS) II.

The PHS II is an ancillary study of the Physicians’ Health Study, a randomized clinical trial assessing whether vitamin supplements prevent cancer and cardiovascular disease. Cognitive evaluations were added to the trial to assess any cognitive impact of supplementation.

The PHS II study extended the follow-up on a subgroup of 7,641 male physicians (average age 73 years) from 1997 through 2003, and also added 7,000 new recruits aged 55 and older in 1998-2001.

Dr. Grodstein and her associates assessed cognitive outcomes in 2,989 subjects who took placebo and 2,967 subjects who took β-carotene for a wide range of durations, ranging from 2 months to 20 years. Verbal memory, immediate and delayed recall, category fluency, and mental state were assessed.

β-Carotene yielded no cognitive benefits in subjects who had taken it for 3 years or less, according to Dr. Grodstein of Harvard School of Public Health, Boston, and her associates.

However, subjects who had taken β-carotene for at least 15 years showed better scores on several cognitive measures than did those who had taken placebo. “In general, the effect of long-term β-carotene treatment was comparable to delaying cognitive aging by 1 to 1.5 years,” the researchers said (Arch. Intern. Med. 2007;167:2184-90).

Nevertheless, in a subset of 4,074 subjects who had further cognitive assessments 2-4 years later, these differences were found to be not statistically significant.

Regarding this last finding, Dr. Kristine Yaffe of the University of California, San Francisco, said in an editorial comment accompanying this report, “it is curious that the authors minimize the results for approximately 4,000 men who had repeated cognitive testing.”

Dr. Yaffe noted that “several trials have examined relatively long durations of antioxidant exposure (up to 10 years) and failed to find an effect of treatment on cognitive outcomes,” (Arch. Intern. Med. 2007;167:2167-8).

“Therefore, clinicians, there is no convincing justification to recommend the use of antioxidant dietary supplements to maintain cognitive performance in cognitively normal adults or in those with mild cognitive impairment. Fur-